logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Phase 3b/4 Study Of Taltz - Quick Facts

Eli Lilly and Company (LLY) said Taltz demonstrated effectiveness in improving the signs and symptoms of active psoriatic arthritis in a Phase 3b/4 SPIRIT-Head-to-Head study. The trial demonstrated that Taltz was more effective than Humira in simultaneously achieving both joint and skin responses after 24 weeks of treatment. Topline results from the study were announced last year.

A total of 566 patients were enrolled in the study. Taltz also met the key secondary endpoints. The safety data were consistent with previously reported results.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products. Hundreds of Facebook employees staged a "virtual walkout" on Monday to protest the company's decision not to act on recent controversial posts by President Donald Trump on the social media platform. The employees criticized Facebook chief executive Mark Zuckerberg's decision to not moderate a post from Trump last Thursday. Doughnut companies Krispy Kreme Doughnut Corp. and Dunkin Donuts are offering free doughnuts to commemorate the upcoming National Doughnut Day on Friday, June 5. In a statement, Krispy Kreme said it is extending National Doughnut Day to National Doughnut Week, with 5 free doughnut days to choose from. The consumers will get any doughnut of choice for free, no purchase necessary, from June 1.
Follow RTT